ClinicalTrials.gg
Status unknownNCT02309047COLAUpdated Oct 20, 2021

The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank

An observational study in Anovulation, sponsored by UMC Utrecht. Status unknown at 1 site in Netherlands. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by UMC Utrecht · Observational

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
5,000
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.

Read the detailed description

Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.

Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")

  1. Low to normal serum follicle-stimulating hormone (FSH) concentrations
  2. Low serum estradiol concentrations

WHO II

  1. Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
  2. Normal serum FSH concentrations (\<12 IU/L)
  3. Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (\<1.0 IU/L), normal thyroid stimulating hormone (TSH) concentrations (0.2 - 4.2 milli-International unit /L), abnormalities on ultrasonography.

Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:

  1. Oligo-/anovulation
  2. Clinical and/ or biochemical hyperandrogenism
  3. Polycystic ovaries on ultrasonography

WHO III

  1. primary ovarian insufficiency (POI): defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
  2. incipient ovarian failure (IOF): defined as normal-ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  3. transient ovarian failure (TOF): defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  4. Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
  5. Early menopause: menopause occurring between age 40 and 45 years.
  6. Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L. Controls For analyses in which comparison with female controls are needed, data will be collected from existing population based cohorts, such as the EPIC cohort (Julius Center), or selected women included in the preconceptional cohort (PC, derived from the Department of Reproductive Medicine and Gynaecology in the University Medical Center Utrecht (UMCU), separate protocol in preparation).

Exclusion criteria

  • Age: younger than 18 yrs.
  • Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).

Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.

  • Age
  • Ethnicity
  • Social economic status and education
  • Intoxications: smoking habits (previous and current), use of alcohol or drugs
  • Medication and medication history
  • Mental health (depression, stress and anxiety)
  • Cycle regularity: age at menarche, use of (oral/intrauterine) contraceptives, mean duration of cycle, variation in cycle duration.
  • Reproductive \& obstetric history: parity, time to pregnancy and pregnancy outcome, subfertility (including treatments)
  • Medical history (including previous gonadotoxic treatment)
  • Family history of diabetes mellitus, early menopause, cycle irregularities, subfertility, cardiovascular disease, endocrinological disease, congenital disorders
  • Basic physical examination: systolic and diastolic blood pressure, height, weight (BMI), waist circumference, hip circumference
  • Assessment of hirsutism, acne, Tanner sexual development stages.
  • Ovarian reserve parameters: antral follicle count, ovarian volume, anti-müllerian hormone (AMH)
  • luteinizing hormone (LH), FSH, prolactin, TSH, estradiol concentrations
  • Androgen levels
  • Lipid spectrum, glucose, insulin, High sensitivity C-reactive protein
  • In POI specifically: bone density as assessed by dual-energy X-ray absorptiometry (DEXA), karyotype, fragile X premutation screening, presence of autoantibodies (against thyroid, ovaries, parietal cells and adrenal gland).

Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.

Relatives of the index patient:

When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.

02

Conditions studied

  • Anovulation

Browse trials for

03

In context

Anovulation

75 studies on the registry are indexed under Anovulation; 7 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 300 across 17 observational studies indexed under Anovulation.

Browse Anovulation studies →

Lead sponsor

UMC Utrecht is the lead sponsor of 364 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.

Eligibility criteria

Inclusion Criteria:

WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")

  1. Low to normal serum FSH concentrations
  2. Low serum estradiol concentrations

WHO II

  1. Amenorrhea or oligomenorrhea (mean cycle >35 days during the last 6 months)
  2. Normal serum FSH concentrations (\<12 IU/L)
  3. Absence of other causes for the cycle disturbance, including: normal prolactin concentrations (\<1.0 IU/L), normal TSH concentrations (0.2 - 4.2 milliunits/L), abnormalities on ultrasonography.

Within women with WHO II status, PCOS is diagnosed when at least 2 of the following criteria are met:

  1. Oligo-/anovulation
  2. Clinical and/ or biochemical hyperandrogenism
  3. Polycystic ovaries on ultrasonography

WHO III

  1. POI: defined as secondary amenorrhea before the age of 40 years and basal FSH > 40 IU/L.
  2. IOF: defined as normal ovulatory cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  3. TOF: defined as irregular cycles with raised basal FSH > 12 IU/L before the age of 40 years.
  4. Poor ovarian response: defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins.
  5. Early menopause: menopause occurring between age 40 and 45 years.
  6. Hypergonadotropic primary amenorrhea: primary amenorrhea with raised basal FSH > 12 IU/L.

Exclusion criteria: Exclusion criteria

  • Age: younger than 18 yrs.
  • Regularly cycling women, with the exception of women with elevated basal FSH concentrations (IOF cases).
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • WHO anovulation

    WHO I, II. III anovulation. See inclusion criteria

06

What researchers measure

Primary outcomes

  1. hormonal classification

    FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH

    Time frame: within 6 weeks

  2. metabolic profile

    total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose

    Time frame: within 6 weeks

  3. ovarian reserve

    anti mullerian hormone, FSH and antral follicle count.

    Time frame: within 6 weeks

Secondary outcomes

  1. autoimmunity in WHO 3- POI patients

    antithyroid peroxidase, antiadrenal, antiparietal and antiovarian antibodies

    Time frame: within 3 months

  2. bone density in WHO 3- POI patients

    a dual-energy x-ray absorptiometry (DEXA) scan

    Time frame: within 3 months

  3. genotype in WHO 3 POI patients

    karotype, fragile X mental retardation 1 gene premutation carriership

    Time frame: within 3 months

07

Study locations

1 of 1 sites recruiting
  • University Medical Center Utrecht
    Utrecht, 3508GA, Netherlands
    Recruiting
08

References and documents

Publications

  • Christ JP, Gunning MN, Meun C, Eijkemans MJC, van Rijn BB, Bonsel GJ, Laven JSE, Fauser BCJM. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818. doi: 10.1210/jc.2018-01787. PubMed 30590587 ↗
  • Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28. PubMed 29605405 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02309047
Lead sponsor
UMC Utrecht
Responsible party
Bart CJM Fauser (professor BCJM Fauser, UMC Utrecht) — Principal investigator
First posted
Dec 5, 2014
Start date
Oct 2004
Primary completion
Jun 2022 (estimated)
Completion
Aug 2023 (estimated)
Last update
Oct 20, 2021

Study contacts

Bart CJ Fauser, professor
principal investigator · UMC Utrecht

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion